<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1394">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04639440</url>
  </required_header>
  <id_info>
    <org_study_id>APHP200983</org_study_id>
    <secondary_id>2020-A02403-36</secondary_id>
    <nct_id>NCT04639440</nct_id>
  </id_info>
  <brief_title>Impact of Adipose Tissue in COVID-19</brief_title>
  <acronym>COVIFAT</acronym>
  <official_title>Impact of Adipose Tissue in COVID-19 : From Pathophysiology to Therapeutic Perspectives</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Overweight or obese patients are particularly exposed to severe forms of COVID-19. Few data&#xD;
      suggest that adipose tissue infected with SARS-CoV-2 could be involved in the onset of the&#xD;
      cytokine storm seen in severe forms of COVID-19. The aim of this study is to determine the&#xD;
      pathogenesis of SARS-CoV-2-infection of adipose tissue. In particular the investigators will&#xD;
      study how this virus enters the adipocyte and how it modulates metabolism and inflammation in&#xD;
      the adipose tissue. From these data, the investigators hope to determine at the adipose&#xD;
      tissue level, original therapeutic targets to modulate the effects of SARS-CoV-2 at the&#xD;
      systemic level.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 23, 2020</start_date>
  <completion_date type="Anticipated">November 23, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 22, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the expression of ACE2 and TMPRSS2 in the subcutaneous and visceral adipose tissue of obese patients. Determination of cells expressing ACE2 and TMPRSS2 in whole human adipose tissue.</measure>
    <time_frame>12 months</time_frame>
    <description>Analysis of the expression of mRNA and ACE2 and TMPRSS2 proteins in the subcutaneous and visceral adipose tissue of normal weight and obese patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Demonstration of entry and replication of SARS-CoV-2 in human adipose tissue</measure>
    <time_frame>12 months</time_frame>
    <description>Infection of human adipocytes in lean and obese subjects by SARS-CoV-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consequences of infection with SARS-CoV-2 on the metabolism and inflammatory state of adipose tissue.</measure>
    <time_frame>12 months</time_frame>
    <description>Assessment of the expression and secretion of inflammatory cytokines (TNF-α, IL-1 , IL-4 , IL-6 , IL-7 , IL-10 , IL-12 , IL-13 , IL-18 ¸ IL-23, INF-α, INF-β) after infection with SARS-CoV-2 of adipose tissue / adipocytes of thin and obese subjects.&#xD;
Evaluation of SARS-CoV-2 infection on the lipolysis of adipose tissue / adipocytes in thin and obese subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consequences of infection with SARS-CoV-2 on the metabolism and inflammatory state of adipose tissue.</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of SARS-CoV-2 infection on the lipolysis of adipose tissue / adipocytes in thin and obese subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of SARS-CoV-2 infection of adipose tissue / adipocytes from thin and obese subjects on endoplasmic reticulum (ER) homeostasis.</measure>
    <time_frame>12 months</time_frame>
    <description>Study whether infection with SARS-CoV-2 activates the RE stress pathways in adipose tissue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target endoplasmic reticulum stress to reduce spread of SARS-CoV-2 from adipose tissue</measure>
    <time_frame>12 months</time_frame>
    <description>Use of RE stress inhibitors on adipocytes infected with SARS-CoV-2 and assess their effect on the maturation of the virus in infected cells.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Obese or overweight patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without overweight</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Adipose tissue</intervention_name>
    <description>Adipose tissue sampling</description>
    <arm_group_label>Obese or overweight patients</arm_group_label>
    <arm_group_label>Patients without overweight</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Obese and thin patients operated on for abdominal vascular surgery.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age greater than or equal to 18 years&#xD;
&#xD;
          -  All patients who are obese or overweight (&gt; 25 kg/m2) or non-obese (&lt; or = 25 kg/m2)&#xD;
             operated for abdominal vascular surgery&#xD;
&#xD;
          -  Beneficiary or entitled to a social security scheme (except AME)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Patient refusal&#xD;
&#xD;
          -  Patient deprived of liberty or subject to a legal protection measure (guardianship,&#xD;
             curatorship)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier BOURRON, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Pitié Salpêtrière - Assistance Publique Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier BOURRON, Dr</last_name>
    <phone>0142178118</phone>
    <email>olivier.bourron@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital de la Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Olivier BOURRON, Dr</last_name>
      <phone>01 42 17 81 18</phone>
      <email>olivier.bourron@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Fabienne FOUFELLE, Dr</last_name>
      <phone>01 42 34 69 23</phone>
      <email>fabienne.foufelle@aphp.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 28, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>November 19, 2020</last_update_submitted>
  <last_update_submitted_qc>November 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adipose tissue</keyword>
  <keyword>Covid19</keyword>
  <keyword>SARS-CoV2</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

